$CYRX
Cryoport, Inc.

2016 Q3 Form 10-Q Financial Statement

#000114420417055868 Filed on November 02, 2017

View on sec.gov

Income Statement

Concept 2016 Q3
Revenue $1.977M
YoY Change 37.58%
Cost Of Revenue $1.180M
YoY Change 17.92%
Gross Profit $797.0K
YoY Change 82.8%
Gross Profit Margin 40.31%
Selling, General & Admin $2.743M
YoY Change 26.99%
% of Gross Profit 344.16%
Research & Development $214.7K
YoY Change 114.05%
% of Gross Profit 26.94%
Depreciation & Amortization $100.0K
YoY Change 150.0%
% of Gross Profit 12.55%
Operating Expenses $2.958M
YoY Change 30.98%
Operating Profit -$2.161M
YoY Change 18.62%
Interest Expense $19.31K
YoY Change -96.79%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change -100.0%
Pretax Income -$2.182M
YoY Change -10.05%
Income Tax $2.878K
% Of Pretax Income
Net Earnings -$2.184M
YoY Change -9.96%
Net Earnings / Revenue -110.47%
Basic Earnings Per Share
Diluted Earnings Per Share -$144.2K
COMMON SHARES
Basic Shares Outstanding 15.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.600M
YoY Change -63.38%
Cash & Equivalents $2.558M
Short-Term Investments
Other Short-Term Assets $600.0K
YoY Change 200.0%
Inventory $82.19K
Prepaid Expenses
Receivables $1.000M
Other Receivables $0.00
Total Short-Term Assets $4.247M
YoY Change -46.91%
LONG-TERM ASSETS
Property, Plant & Equipment $1.373M
YoY Change 71.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K
YoY Change
Total Long-Term Assets $1.753M
YoY Change 94.75%
TOTAL ASSETS
Total Short-Term Assets $4.247M
Total Long-Term Assets $1.753M
Total Assets $6.000M
YoY Change -32.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M
YoY Change 33.33%
Accrued Expenses $400.0K
YoY Change 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $700.0K
YoY Change -30.0%
Total Short-Term Liabilities $2.292M
YoY Change 4.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.292M
Total Long-Term Liabilities $0.00
Total Liabilities $2.292M
YoY Change 4.19%
SHAREHOLDERS EQUITY
Retained Earnings -$119.3M
YoY Change
Common Stock $122.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.698M
YoY Change
Total Liabilities & Shareholders Equity $6.000M
YoY Change -32.58%

Cashflow Statement

Concept 2016 Q3
OPERATING ACTIVITIES
Net Income -$2.184M
YoY Change -9.96%
Depreciation, Depletion And Amortization $100.0K
YoY Change 150.0%
Cash From Operating Activities -$1.530M
YoY Change 42.99%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K
YoY Change -65.22%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$80.00K
YoY Change -65.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -360.0K
YoY Change -106.03%
NET CHANGE
Cash From Operating Activities -1.530M
Cash From Investing Activities -80.00K
Cash From Financing Activities -360.0K
Net Change In Cash -1.970M
YoY Change -142.18%
FREE CASH FLOW
Cash From Operating Activities -$1.530M
Capital Expenditures -$80.00K
Free Cash Flow -$1.450M
YoY Change 72.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
656221 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14517297 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2935432 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
10872983 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-2689397 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5247425 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
344798 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
214680 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
825377 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8878 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1843 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
494957 USD
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1929818 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
491980 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
271521 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6130 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
78518 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2529858 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2337936 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-76222 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-147837 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
11636 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2503 USD
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
280293 USD
us-gaap Increase Decrease In Long Term Receivables Current
IncreaseDecreaseInLongTermReceivablesCurrent
385944 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
755 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
67587 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
200952 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-124913 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
209759 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
13039 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2363110 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4953374 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1229671 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
666455 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1281204 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-671455 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11405924 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2244247 USD
cyrx Proceeds From Rights Offering Net Of Offering Cost
ProceedsFromRightsOfferingNetOfOfferingCost
0 USD
cyrx Proceeds From Rights Offering Net Of Offering Cost
ProceedsFromRightsOfferingNetOfOfferingCost
-998156 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3767594 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
200000 USD
CY2017Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.88
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2558028 USD
cyrx Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
0 USD
cyrx Proceeds From Issuance Of Common Stock Accrued Board Of Director Compensation
ProceedsFromIssuanceOfCommonStockAccruedBoardOfDirectorCompensation
26901 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
51533 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-22576 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
317858 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1068055 USD
CY2017Q1 us-gaap Legal Fees
LegalFees
5000 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
9600 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
43200 USD
CY2017Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0 USD
CY2016Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
11400 USD
cyrx Consulting Service Fee
ConsultingServiceFee
145600 USD
cyrx Consulting Service Fee
ConsultingServiceFee
299000 USD
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10908504 shares
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
70000 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
75000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17604283 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25217535 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17604283 shares
cyrx Reduction Of Accounts Payable For Returned Fixed Assets
ReductionOfAccountsPayableForReturnedFixedAssets
225106 USD
cyrx Reduction Of Accounts Payable For Returned Fixed Assets
ReductionOfAccountsPayableForReturnedFixedAssets
0 USD
cyrx Stock Issued During Period Shares Cashless Exercise Of Warrants
StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
105660 shares
CY2017Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
193699 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
248500 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
cyrx Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
P90D
cyrx Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Exercises In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodIntrinsicValue
5100000 USD

Files In Submission

Name View Source Status
0001144204-17-055868-index-headers.html Edgar Link pending
0001144204-17-055868-index.html Edgar Link pending
0001144204-17-055868.txt Edgar Link pending
0001144204-17-055868-xbrl.zip Edgar Link pending
cyrx-20170930.xml Edgar Link completed
cyrx-20170930.xsd Edgar Link pending
cyrx-20170930_cal.xml Edgar Link unprocessable
cyrx-20170930_def.xml Edgar Link unprocessable
cyrx-20170930_lab.xml Edgar Link unprocessable
cyrx-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv478244_10q.htm Edgar Link pending
tv478244_ex31-1.htm Edgar Link pending
tv478244_ex31-2.htm Edgar Link pending
tv478244_ex32-1.htm Edgar Link pending
tv478244_img1.jpg Edgar Link pending